Get the Daily Brief
Latest Biotech News
Revolution Medicines’ daraxonrasib swings trial-level momentum and taps capital markets
Revolution Medicines reported Phase 3 results for daraxonrasib (RMC-6236), a RAS-targeting inhibitor in metastatic pancreatic ductal adenocarcinoma, showing longer progression-free survival and...
Cochrane verdict reignites the anti-amyloid Alzheimer’s drug debate
A sweeping Cochrane review concluded that anti-amyloid antibody drugs in Alzheimer’s disease produce “no meaningful difference” for patients with mild cognitive impairment or mild dementia. The...
MeiraGTx buys back failed J&J eye gene therapy, while Storm funds a new sarcoma trial
MeiraGTx agreed to buy back full rights to bota-vec, an eye gene therapy previously backed by Johnson & Johnson after a Phase 3 failure in X-linked retinitis pigmentosa. The deal brings the asset...
Beeline Medicines launches from Bain and brings Bristol Myers immune assets back into play
Bain Capital launched Beeline Medicines, a new company seeded with five Bristol Myers Squibb immunology programs after the licensing deal that took place last year. The startup emerged from...
FDA continues to scrutinize compounded peptides as regulatory stance shifts
The FDA is moving toward easing restrictions on certain peptides by convening advisory panel discussions about whether compounding pharmacies should be allowed to make products that were...
Cancer diagnostics get a major Roche expansion via Saga MRD testing
Roche said it will acquire Saga Diagnostics for up to $595 million through Foundation Medicine, expanding its molecular residual disease testing portfolio. The deal includes milestone payments and...
AbbVie expands pain portfolio via Haisco licensing deal
AbbVie secured rights to develop, manufacture, and commercialize Haisco’s portfolio of pain compounds outside mainland China, Hong Kong, and Macau under a licensing agreement worth $745 million....
Terremoto raises $108M to advance oral AKT1 inhibitors into the clinic
Terremoto Biosciences raised $108 million in a Series C to develop small-molecule medicines targeting AKT, funding further first-in-human progress for oral candidates. New investors include RA...
Diagnostics & med-tech earnings after Exact Sciences
Abbott reported that Diagnostics revenue rose 6% year over year to $2.18 billion in Q1 2026, marking the first quarter of results after completion of its Exact Sciences acquisition. Core...
Obesity drugs face new FDA safety scrutiny
New FDA documents show Eli Lilly has been asked to evaluate liver and cardiovascular risks for its recently approved obesity pill Foundayo as part of ongoing trials, following approval conditions....
Oncology: RAS-driven pancreatic cancer capitalizes on Phase 3 readout
Revolution Medicines priced a large concurrent offering—its follow-on stock and debt raise totaling $2 billion—just days after topline Phase 3 results for daraxonrasib in metastatic pancreatic...
Oncology therapeutics: dual-payload ADC acquisition accelerates pipeline
Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million to expand its oncology antibody-drug conjugate pipeline, betting on dual-payload delivery to improve tumor killing and...
Regulatory: FDA’s gene-editing safety draft guidance
The FDA released draft guidance outlining how sponsors should use next-generation sequencing and bioinformatics in nonclinical studies to assess safety risks for genome-edited human gene...
Regulatory: next European path for Roche’s Elevidys
Roche said it will run another Phase 3 trial of Duchenne muscular dystrophy gene therapy Elevidys aimed at supporting European approval after the European regulators issued a negative review last...
Clinical trials: FIRMA entry of FDA-approved first-in-class in rare kidney disease
Travere Therapeutics’ Filspari (sparsentan) cleared a key regulatory milestone by becoming the first fully FDA-approved treatment for focal segmental glomerulosclerosis (FSGS). The expanded label...
Autoimmune immunology: Bain-backed Beeline launches with BMS assets
Bain Capital backed Beeline Medicines emerged from stealth with a $300 million Series A and five immunology programs licensed from Bristol Myers Squibb. The startup’s pipeline includes afimetoran,...
CRO/CDMO infrastructure: Tempus to distribute WGS assay for multiple myeloma
Tempus announced it will distribute Predicta Biosciences’ whole-genome sequencing-based GenoPredicta assay for multiple myeloma, bringing the test into Tempus’ diagnostic ecosystem. GenoPredicta...
Ventures: Terremoto raises $108M for AKT inhibitor programs
Terremoto Biosciences raised $108 million in a Series C financing to advance small-molecule drugs targeting AKT, with the company describing its covalency technology approach to improve efficacy...
Oncology financing and late-stage readouts
Revolution Medicines priced a $1.5 billion follow-on offering, following top-line Phase 3 results for its RAS inhibitor daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The transaction...
Tightening gene-editing safety expectations at FDA
The FDA released draft guidance focused on using next-generation sequencing and bioinformatics to evaluate safety for genome-edited gene therapy products. The document centers on nonclinical...